Approval · Notice of Compliance 23034 · 2019
SATIVEX: Notice of Compliance 23034
Issued December 12, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23034
- Date
- December 12, 2019
- Company
- Gw Pharma Limited
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To remove the cancer pain indication and neuropathic pain indication approved under the noc/c policy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SATIVEX | Not yet assigned | — |
Medicinal ingredients
- DELTA-9-TETRAHYDROCANNABINOL 27 MG per ML
- CANNABIDIOL 25 MG per ML